Y-mAbs’ GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation 13 December 2019
NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
COPENHAGEN, Denmark, November 21, 2019 / B3C newswire / — MC2 Therapeutics, an emerging pharmaceutical... Read more
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq:... Read more
EuropaBio hosts 12th annual Industrial Biotech and Bioeconomy Conference – #EFIB2019 As the new... Read more
The BRIDGE – Translational Excellence Programme is seeking mentor teams who wish to combine their research... Read more
Kim Stratton to succeed Anders Hinsby, effective October 1, 2019 Copenhagen, July 15, 2019 – Orphazyme... Read more
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more